Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Vertex Pharmaceuticals

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities6.40%
Size of stake in company0.20%
Market capitalizationUSD 179.3 bn

Sector

Orphan Disease

Main candidate

Trikafta

Main indications

Cystic Fibrosis

About the company

Vertex is a biotechnology company focused primarily on treatments for the genetic disease cystic fibrosis, as well as other unmet medical needs. Founded in 1989, the company is headquartered in Cambridge, Massachusetts, in the US, with operations across Europe, Australia, and Latin America. The company has a number of approved medicines that treat the underlying cause of cystic fibrosis – a rare and life-threatening genetic disease. The approved drugs in this disease area include Kalydeco, Orkambi, Symdeko, and Trikafta. Besides cystic fibrosis, Vertex has a pipeline of investigational small molecule medicines for other serious diseases where it has deep insight into causal human biology, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and pain. In addition, the company has a partnership with Crispr Therapeutics for the development and commercialization of Casgevy, the first ex-vivo cell therapy ever been approved by the US FDA (December 2023) for patients with sickle cell therapy.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.